FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897219229> ?p ?o ?g. }

• W2897219229 endingPage "viii448" @default.
• W2897219229 startingPage "viii448" @default.
• W2897219229 abstract "Background: Combination ipilimumab and nivolumab is a highly active systemic therapy for metastatic melanoma but can cause significant toxicity. How best to integrate this combination into clinical practice, in real-world patients, and in the setting of BRAF targeted therapy, is not clear. We sought to explore the safety and efficacy of combination ipilimumab and nivolumab in such a population. Methods: Consecutive patients with unresectable stage IIIC/IV melanoma commenced on ipilimumab and nivolumab via an early access scheme across 10 tertiary melanoma institutions in Australia were identified retrospectively. Data collected included demographics, prior and subsequent systemic treatments, toxicity, RECIST response and survival outcomes. Results: 152 patients were included for analysis, including 60 (39%) treatment-naïve and 33 (22%) who had failed first-line BRAF/MEK inhibitors and then treated with combination therapy second-line. In the whole cohort, most patients had a high AJCC M stage (63% M1c, 26% M1d) and elevated LDH (55%), with similar distribution of adverse features in the treatment naïve and BRAF/MEK failure subgroups. Treatment-related adverse events occurred in 102 (67%) patients, grade 3-5 in 38% (1 death from immune myocarditis). The objective response rate was 41% in the whole cohort, 57% (17% complete) in treatment naïve, and only 21% (3% complete) in BRAF/MEK failure patients. Median progression-free survival was 4.0 months (95% CI, 3.0 to 6.0) in the whole cohort, 11.0 months (95% CI, 6.0 - NR) in treatment-naïve patients, and 2.0 months (95% CI, 1.4 - 4.6) in BRAF/MEK failure patients. Conclusions: Combination ipilumumab and nivolumab can be used safely and effectively in a real-world population, including in patients that are heavily pre-treated and those with adverse disease characteristics. While first-line efficacy appears comparable to that seen in trial populations, BRAF-mutant patients who have failed prior BRAF/MEK inhibitors are less likely to respond, supporting first-line use of combination immunotherapy in the majority of newly diagnosed poor prognosis metastatic melanoma patients. Legal entity responsible for the study: A. Menzies. Funding: Has not received any funding. Disclosure: H.C. Dearden: Travel expenses support: MSD. R. Mason: Travel expenses support: Bristol-Myers Squibb. J.A. Soon: Travel expenses support: Pfizer. M. Randhawa: Travel expenses support: Merck. A. Mant: Consultancy: Novartis. L. Warburton: Travel expenses support: MSD. T. Meniawy: Honoraria; Consultancy: AstraZeneca/MedImmune; Research funding: Incyte, BeiGene, AstraZeneca/MedImmune, Regeneron, Bayer, Roche/Genetech, Bristol Myers Squibbs, Merck Serono Ltd; Travel expenses support: Roche/Genetech. A. Guminski: Consultancy for Roche, Regeneron, Eisai, Sun Pharma, Bristol Myers Squibbs; Travel and expenses support: Sun Pharma, Bristol Myers Squibb. S. Ali: Honoraria and consultancy: Bristol Myers Squibb. G.V. Long: Consultancy: Bristol-Myers Squibb, Roche/Genentech, Amgen, Merck, Novartis, Array BioPharma, Pierre Fabre, Incycte; Honoraria: Bristol-Myers Squibb, Merck, Roche, Novartis, Incycte. M.S. Carlino: Consultancy: Bristol-Myers Squibb, MSD, Amgen, Novartis, Pierre Fabre; Honoraria: Bristol-Myers Squibb, MSD, Novartis. M. Millward: Consultancy: AstraZeneca, MSD, Roche, Bristol Myers Squibbs; Travel expenses support: Roche, MSD, Bristol Myers Squibb. V.G. Atkinson: Honoraria; Novartis, Bristol Myers Squibbs; Consultancy: Novartis, Pierre Fabre, Bristol Myers Squibbs, Merck Serono Ltd, MSD; Travel expenses support: Bristol Myers Squibb. A.M. Menzies: Consultancy: MSD, Novartis, Pierre Fabre, Bristol-Myers Squibb, Roche; Travel expenses support: Bristol-Myers Squibb. All other authors have declared no conflicts of interest." @default.
• W2897219229 created "2018-10-26" @default.
• W2897219229 creator A5000291176 @default.
• W2897219229 creator A5010491777 @default.
• W2897219229 creator A5019509418 @default.
• W2897219229 creator A5025798657 @default.
• W2897219229 creator A5040969461 @default.
• W2897219229 creator A5043980066 @default.
• W2897219229 creator A5048445145 @default.
• W2897219229 creator A5054723003 @default.
• W2897219229 creator A5056692074 @default.
• W2897219229 creator A5065006250 @default.
• W2897219229 creator A5070576000 @default.
• W2897219229 creator A5071437418 @default.
• W2897219229 creator A5073719611 @default.
• W2897219229 creator A5078906306 @default.
• W2897219229 creator A5079833339 @default.
• W2897219229 creator A5080065227 @default.
• W2897219229 creator A5083061830 @default.
• W2897219229 creator A5088903876 @default.
• W2897219229 creator A5090545021 @default.
• W2897219229 date "2018-10-01" @default.
• W2897219229 modified "2023-09-26" @default.
• W2897219229 title "Combined ipilimumab and nivolumab first-line and after BRAF-directed targeted therapies in advanced melanoma patients" @default.
• W2897219229 doi "https://doi.org/10.1093/annonc/mdy289.012" @default.
• W2897219229 hasPublicationYear "2018" @default.
• W2897219229 type Work @default.
• W2897219229 sameAs 2897219229 @default.
• W2897219229 citedByCount "1" @default.
• W2897219229 countsByYear W28972192292021 @default.
• W2897219229 crossrefType "journal-article" @default.
• W2897219229 hasAuthorship W2897219229A5000291176 @default.
• W2897219229 hasAuthorship W2897219229A5010491777 @default.
• W2897219229 hasAuthorship W2897219229A5019509418 @default.
• W2897219229 hasAuthorship W2897219229A5025798657 @default.
• W2897219229 hasAuthorship W2897219229A5040969461 @default.
• W2897219229 hasAuthorship W2897219229A5043980066 @default.
• W2897219229 hasAuthorship W2897219229A5048445145 @default.
• W2897219229 hasAuthorship W2897219229A5054723003 @default.
• W2897219229 hasAuthorship W2897219229A5056692074 @default.
• W2897219229 hasAuthorship W2897219229A5065006250 @default.
• W2897219229 hasAuthorship W2897219229A5070576000 @default.
• W2897219229 hasAuthorship W2897219229A5071437418 @default.
• W2897219229 hasAuthorship W2897219229A5073719611 @default.
• W2897219229 hasAuthorship W2897219229A5078906306 @default.
• W2897219229 hasAuthorship W2897219229A5079833339 @default.
• W2897219229 hasAuthorship W2897219229A5080065227 @default.
• W2897219229 hasAuthorship W2897219229A5083061830 @default.
• W2897219229 hasAuthorship W2897219229A5088903876 @default.
• W2897219229 hasAuthorship W2897219229A5090545021 @default.
• W2897219229 hasBestOaLocation W28972192291 @default.
• W2897219229 hasConcept C121608353 @default.
• W2897219229 hasConcept C126322002 @default.
• W2897219229 hasConcept C141071460 @default.
• W2897219229 hasConcept C143998085 @default.
• W2897219229 hasConcept C167135981 @default.
• W2897219229 hasConcept C197934379 @default.
• W2897219229 hasConcept C2775832928 @default.
• W2897219229 hasConcept C2776999253 @default.
• W2897219229 hasConcept C2777658100 @default.
• W2897219229 hasConcept C2777701055 @default.
• W2897219229 hasConcept C2780030458 @default.
• W2897219229 hasConcept C2781230642 @default.
• W2897219229 hasConcept C2781433595 @default.
• W2897219229 hasConcept C2908647359 @default.
• W2897219229 hasConcept C502942594 @default.
• W2897219229 hasConcept C71924100 @default.
• W2897219229 hasConcept C72563966 @default.
• W2897219229 hasConcept C99454951 @default.
• W2897219229 hasConceptScore W2897219229C121608353 @default.
• W2897219229 hasConceptScore W2897219229C126322002 @default.
• W2897219229 hasConceptScore W2897219229C141071460 @default.
• W2897219229 hasConceptScore W2897219229C143998085 @default.
• W2897219229 hasConceptScore W2897219229C167135981 @default.
• W2897219229 hasConceptScore W2897219229C197934379 @default.
• W2897219229 hasConceptScore W2897219229C2775832928 @default.
• W2897219229 hasConceptScore W2897219229C2776999253 @default.
• W2897219229 hasConceptScore W2897219229C2777658100 @default.
• W2897219229 hasConceptScore W2897219229C2777701055 @default.
• W2897219229 hasConceptScore W2897219229C2780030458 @default.
• W2897219229 hasConceptScore W2897219229C2781230642 @default.
• W2897219229 hasConceptScore W2897219229C2781433595 @default.
• W2897219229 hasConceptScore W2897219229C2908647359 @default.
• W2897219229 hasConceptScore W2897219229C502942594 @default.
• W2897219229 hasConceptScore W2897219229C71924100 @default.
• W2897219229 hasConceptScore W2897219229C72563966 @default.
• W2897219229 hasConceptScore W2897219229C99454951 @default.
• W2897219229 hasLocation W28972192291 @default.
• W2897219229 hasOpenAccess W2897219229 @default.
• W2897219229 hasPrimaryLocation W28972192291 @default.
• W2897219229 hasRelatedWork W2138469314 @default.
• W2897219229 hasRelatedWork W2225212058 @default.
• W2897219229 hasRelatedWork W2788498597 @default.
• W2897219229 hasRelatedWork W2947988614 @default.
• W2897219229 hasRelatedWork W2955428297 @default.
• W2897219229 hasRelatedWork W2965431126 @default.
• W2897219229 hasRelatedWork W3005150264 @default.
• W2897219229 hasRelatedWork W4220795664 @default.

• next